President Trump’s drug pricing deal would lower costs for obesity treatments, introducing consumer prices that vary by drug and dose. Starting doses of two yet-to-be-released pills — Eli Lilly’s orforglipron and an oral, higher-dose version of Novo Nordisk’s Wegovy — could be $149 a month; Lilly says higher orforglipron doses will be capped at $399. Wegovy’s average direct-to-consumer price is set at $350 monthly, while Zepbound ranges from $299 to $449. The pills have FDA fast-track status, with decisions expected in coming months.

Prepared by Christopher Adams and reviewed by editorial team.